GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (TSE:4527) » Definitions » ROE %

Rohto Pharmaceutical Co (TSE:4527) ROE % : 16.18% (As of Dec. 2023)


View and export this data going back to 1962. Start your Free Trial

What is Rohto Pharmaceutical Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Rohto Pharmaceutical Co's annualized net income for the quarter that ended in Dec. 2023 was 円38,252 Mil. Rohto Pharmaceutical Co's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was 円236,488 Mil. Therefore, Rohto Pharmaceutical Co's annualized ROE % for the quarter that ended in Dec. 2023 was 16.18%.

The historical rank and industry rank for Rohto Pharmaceutical Co's ROE % or its related term are showing as below:

TSE:4527' s ROE % Range Over the Past 10 Years
Min: 7.56   Med: 9.04   Max: 13.91
Current: 13.91

During the past 13 years, Rohto Pharmaceutical Co's highest ROE % was 13.91%. The lowest was 7.56%. And the median was 9.04%.

TSE:4527's ROE % is ranked better than
75.44% of 1820 companies
in the Consumer Packaged Goods industry
Industry Median: 6.405 vs TSE:4527: 13.91

Rohto Pharmaceutical Co ROE % Historical Data

The historical data trend for Rohto Pharmaceutical Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rohto Pharmaceutical Co ROE % Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.57 11.39 11.34 12.64 13.60

Rohto Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.56 9.09 16.92 13.25 16.18

Competitive Comparison of Rohto Pharmaceutical Co's ROE %

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co's ROE % Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's ROE % distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's ROE % falls into.



Rohto Pharmaceutical Co ROE % Calculation

Rohto Pharmaceutical Co's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=26377/( (178398+209568)/ 2 )
=26377/193983
=13.60 %

Rohto Pharmaceutical Co's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=38252/( (232939+240037)/ 2 )
=38252/236488
=16.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Rohto Pharmaceutical Co  (TSE:4527) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=38252/236488
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(38252 / 293176)*(293176 / 338558.5)*(338558.5 / 236488)
=Net Margin %*Asset Turnover*Equity Multiplier
=13.05 %*0.866*1.4316
=ROA %*Equity Multiplier
=11.3 %*1.4316
=16.18 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=38252/236488
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (38252 / 56104) * (56104 / 57184) * (57184 / 293176) * (293176 / 338558.5) * (338558.5 / 236488)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6818 * 0.9811 * 19.51 % * 0.866 * 1.4316
=16.18 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Rohto Pharmaceutical Co ROE % Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rohto Pharmaceutical Co (TSE:4527) Business Description

Traded in Other Exchanges
Address
1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (TSE:4527) Headlines

No Headlines